Outline the therapeutic options with rationale for the treatment of right ventricular dysfunction in an ICU patient.
By titrating fluid if hypovolaemic or diurese or dialyse off volume if required.
Most conditions that lead to RV dysfunction in the ICU are due to increased afterload & an enlarging RV may worsen coronary perfusion as well as impede LV filling through ventricular interdependence. Hence reducing RV excessive preload can both reduce RV stretch and function as well as improving the performance of the LV.
In those specific circumstances where RV output is impaired due to contractile dysfunction e.g. in the setting of a normal afterload, a higher preload is needed to maintain forward flow. e.g. RV infarction
General measures to improve contractility:
Avoid over stretch of the RV free wall with optimisation of preload and afterload.
Maintenance of Sinus rhythm – correct electrolytes, acidaemia, use of anti-dysrhythmics, and if needed AV sequential pacing.
1. Noradrenaline improves coronary perfusion in the RV but will increase pulmonary vascular resistance (PVR); however, the overall impact is that noradrenaline has been shown be helpful in RV dysfunction
2. Adrenaline improves RV contractility without increasing (PVR)
3. Milrinone (50mcg/kg bolus -> 0.2-0.8mcg/kg/min) a PD3 inhibitor improves inotropy and promotes vasodilatation (systemic and pulmonary). Can be associated with hypotension so paired with noradrenalin.
4. Dobutamine -can be paired with noradrenaline but can cause tachyarrhythmias
5. Levosimendin is a calcium sensitiser and can improve RV function in left heart disease.
Mechanical devices to support the RV: whist we treat the underlying cause. These include: ECMO; RV assist devices/Impella.
Excessive afterload plays some role in nearly all cases of acute RV failure.
Reduction best achieved by a range of general measures and specific pharmaco-therapies including pulmonary vasodilators.
General measures to improve hypoxia hypercarbia and acidosis
1. Oxygen therapy
2. Lung protective mechanical ventilation using the lowest effective plateau pressure tidal volume and PEEP whilst avoiding hypoxia and hypercarbia.
e.g. Vt 4-6ml/kg Ideal BW; minimise PEEP; P plat < 30 mmHg; treat hypercarbia, acidosis. (PVR lowest at FRC)
3. Avoidance of hypothermia
4. Treatment of thromboembolic disease if acute cor pulmonale from PE.
Several classes of drug in this setting and all have the potential to cause systemic hypotension and blunt hypoxic pulmonary vasoconstriction and can worsen VQ mismatch.
a) Inhaled nitric oxide 20-40ppm; rapid onset short offset short half-life is the inhaled vasodilator of choice in the critically ill. Has been shown to improve RV ejection fraction and end-diastolic volume in these patients, improve pulmonary hemodynamics and mixed venous oxygen saturation in patients with acute RV failure.
b) Inhaled prostacyclin analogues have been shown to be effective in post cardiac surgery patients with pulmonary hypertension, refractory hypoxaemia or right heart dysfunction.
The level of detail in template was not required. Discussion of preload optimisation, contractility and pulmonary vasodilation was required for a pass.
This is the second question on right heart failure in the same paper, the other being Question 5 (focusing on the investigations for right heart failure). Management of RV dysfunction is discussed in (much) greater detail elsewhere, and so the nitty-gritty of it are omitted from this discussion section because under the stress of years of (many) RV failure questions that section has hypertrophied to a completely unmanageable thickness, to the point where it no longer functions as a revision resource for the time-poor candidate.
- Preload management:
- Acute failure: increase preload to CVP 8-12 mmHg
- Chronic failure: decrease preload to CVP 8-12 mmHg
- Titrate using PA catheter (CO measurements)
- Afterload management:
- Prevent pulmonary vasoconstriction:
- Keep PEEP 6-10 cm H2O
- Keep SpO2 >92%
- Keep PaCO2 35-45 mmHg
- Keep pH 7.35-7.45
- Avoid high dose noradrenaline
- But: keep systemic BP at least above pulmonary BP
- Increase pulmonary vasodilation:
- Nitric oxide
- IV or inhaled prostacycline
- Bosentan, ambrisentan
- Sildenafil, tadalafil
- Prevent pulmonary vasoconstriction:
- Dobutamine, for where PA pressure is normal
- Milrinone, for where PA pressure is raised
- Levosimendan, for where you really need a cardiac output boost
- 60-100 appears to be a safe range (no specific diastolic benefit with low rates, no specific diastolic disadvantage with high rates)
- Sinus rhythm might be favoured in RV failure due to acute RV infarction (where there is no preexisting pulmonary hypertension).
Haddad, François, et al. "Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure." Circulation 117.13 (2008): 1717-1731.
Brida, Margarita, Gerhard-Paul Diller, and Michael A. Gatzoulis. "Systemic right ventricle in adults with congenital heart disease: anatomic and phenotypic spectrum and current approach to management." Circulation 137.5 (2018): 508-518.
Kucher, Nils, et al. "Double-chambered right ventricle." Circulation 103.21 (2001): e105-e106.
Tonelli, Adriano R., et al. "Peripheral pulmonary artery stenosis as a cause of pulmonary hypertension in adults." Pulmonary circulation 5.1 (2015): 204-210.
Blake, Hu A., Robert J. Hall, and William C. Manion. "Anomalous pulmonary venous return." Circulation 32.3 (1965): 406-414.
Vavuranakis, Manolis, Charles A. Bush, and Harisios Boudoulas. "Coronary artery fistulas in adults: incidence, angiographic characteristics, natural history." Catheterization and cardiovascular diagnosis 35.2 (1995): 116-120.
Kulasegaram, Kulamakan, et al. "The alignment imperative in curriculum renewal." Medical teacher (2018): 1-6.
Marcus, Frank I., et al. "Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria." Circulation 121.13 (2010): 1533-1541.
Gorter, Thomas M., et al. "Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta‐analysis." European journal of heart failure18.12 (2016): 1472-1487.
Gorter, Thomas M., et al. "Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology." European journal of heart failure 20.1 (2018): 16-37.
Zamora, Rolando, James H. Moller, and Jesse E. Edwards. "Double-outlet right ventricle: anatomic types and associated anomalies." Chest 68.5 (1975): 672-677.
Mant, Jonathan, et al. "Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care." (2009).
Voelkel, Norbert F., et al. "Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure." Circulation 114.17 (2006): 1883-1891.
Ventetuolo, Corey E., and James R. Klinger. "Management of acute right ventricular failure in the intensive care unit." Annals of the American Thoracic Society 11.5 (2014): 811-822.
Vlahakes, Gus J., Kevin Turley, and J. I. E. Hoffman. "The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations." Circulation 63.1 (1981): 87-95.
Dell'Italia, L. J., et al. "Comparative effects of volume loading, dobutamine, and nitroprusside in patients with predominant right ventricular infarction." Circulation 72.6 (1985): 1327-1335.
Bart, Bradley A., et al. "Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network." Journal of cardiac failure 18.3 (2012): 176-182.
Patil, Nitin Tanajirao. "Strategies in patients with right ventricular failure on mechanical ventilation." Indian Journal of Respiratory Care 7.1 (2018): 22.
Schmitt, Jean-Marie, et al. "Positive end-expiratory pressure titration in acute respiratory distress syndrome patients: impact on right ventricular outflow impedance evaluated by pulmonary artery Doppler flow velocity measurements." Critical care medicine 29.6 (2001): 1154-1158.
Lahm, Tim, et al. "Medical and surgical treatment of acute right ventricular failure." Journal of the American College of Cardiology 56.18 (2010): 1435-1446.
Kiely, David G., Robert I. Cargill, and Brian J. Lipworth. "Effects of hypercapnia on hemodynamic, inotropic, lusitropic, and electrophysiologic indices in humans." Chest 109.5 (1996): 1215-1221.
Sylvester, J. T., et al. "Hypoxic pulmonary vasoconstriction." Physiological reviews 92.1 (2012): 367-520.
Zamanian, Roham T., et al. "Management strategies for patients with pulmonary hypertension in the intensive care unit." Critical care medicine 35.9 (2007): 2037-2050.
Carvalho, Carlos Roberto Ribeiro, et al. "Temporal hemodynamic effects of permissive hypercapnia associated with ideal PEEP in ARDS." American journal of respiratory and critical care medicine 156.5 (1997): 1458-1466.
Rudolph, A. M., and Stanley Yuan. "Response of the pulmonary vasculature to hypoxia and H+ ion concentration changes." The Journal of clinical investigation 45.3 (1966): 399-411.
Bousvaros, George A. "Effects of norepinephrine on human pulmonary circulation." British heart journal 24.6 (1962): 738.
Bhorade, Sangeeta, et al. "Response to inhaled nitric oxide in patients with acute right heart syndrome." American journal of respiratory and critical care medicine 159.2 (1999): 571-579.
Charl, J., et al. "Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery." The Journal of thoracic and cardiovascular surgery127.4 (2004): 1058-1067.
Ferrario, Maurizio, et al. "Hemodynamics of volume loading compared with dobutamine in severe right ventricular infarction." American Journal of Cardiology 74.4 (1994): 329-333.
Kerbaul, François, et al. "Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure." Critical care medicine 32.4 (2004): 1035-1040.
Eichhorn, Eric J., et al. "Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy." American Journal of Cardiology 60.16 (1987): 1329-1333
Hansen, Mona Sahlholdt, Asger Andersen, and Jens Erik Nielsen-Kudsk. "Levosimendan in pulmonary hypertension and right heart failure." Pulmonary circulation 8.3 (2018): 2045894018790905.
Kleber, Franz X., et al. "Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study." The Journal of Clinical Pharmacology 49.1 (2009): 109-115.
Qiu, Jiayong, et al. "Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis." Life sciences 184 (2017): 30-36.
Dubin, Anne M., et al. "Electrical resynchronization: a novel therapy for the failing right ventricle." Circulation 107.18 (2003): 2287-2289.
Skhiri, Mehdi, et al. "Evidence-based management of right heart failure: a systematic review of an empiric field." Revista Española de Cardiología (English Edition) 63.4 (2010): 451-471.